
International Journal of Pharmacy Teaching & Practices

Vol 4, issue 1 March, 2013

ISSN: 1986-8111



www.ijptp.iomcworld.com contact us: ijourptp@gmail.com

Published by: DRUNPP Association of Sarajevo, Bosnia & Herzegovinc

Click to enable Adobe Flash Player

Click to enable Adobe Flash Player

Any questions or

comments may be address to official email

ijourptp@gmail.com



Vol 4, Issue 1, 2013 March

PHARMACY EDUCATION

Glimpse of Pharmaceutical Education in Nepal

Dibyajyoti Saha*, Swati Paul (pp. 438-441)

Awareness of Pictograms among the Undergraduate Pharmacy Students in a Pharmacy College in Karnataka, India: A Preliminary Study

Banstola A* (pp. 442-4446)

PHARMACEUTICAL TECHNOLOGY

Anti Salmonella activity of nitric oxide donor and antibiotic: In vitro studies

S.S.Haque (pp. 447-4450)

Antioxidant enzyme activities assay and thiobarbituric acid reactive substances concentration following administration of ghrelin in the rat kidney

Shima Neamati *1, Masoud Alirezaei ², Arash Kheradmand ³, Marzieh Rashidipour ⁴, Mohammad Reza Saki ⁵ (pp. 451-457)

Extraction, Pharmacological Evaluation and Formulation of Selected Medicinal Herbs for Antidiabetic Activity

R.Margret Chandira*, B.Jaykar. (pp. 458-482)

In vitro Culture and Agrobacterium Mediated Transformation in High Altitude Tomato (Lycopersicon esculentum Mill.) Cultivar Shalimar

C. Janani¹, Dr. S. Girija², Dr. B. D. Ranjitha Kumari^{3*} (pp. 483-488)

Distribution Coefficient of Coumarin-Based Compounds Containing a Chalcone Moiety

Selma ŠPIRTOVIĆ-HALILOVIĆ* 1, Davorka ZAVRŠNIK1, Belma IMAMOVIĆ2, Ervina BEČIĆ2 (pp. 489-491)

PUBLIC HEALTH

The Effect of Regular Human Insulin and Glulisine Insulin on Blood Glucose Concentration in Diabetic
Nephropathy Patients with Hyperglycemia

¹Budi Suprapti, ²agung Pranoto, ¹ardian Avrilena Mp., ¹sumarno, ¹samirah, ¹wenny Putri Nilamsari (pp. 492-497)

Knowing about Ewing Sarcoma

Diana Laila Ramatillah^{1*}, Syed Wasif Gillani² (pp. 498-503)

Prevalence of self-medication of antibiotics among people in Bangladesh

Nishat Chowdhury* , Mohammad Rashedul Islam, Md. Mehedi Hasan, Md. Mahmudur Rouf (pp. 504-510

Assessment of Engxaparin anti-Xa activity and Treatment Efficacy's Evaluation

Guy-Armel Bounda*, Hao Zhi Hui, GE Wei Hong, YU Feng (pp. 511-515)

<u>Skills Acquired during Baccalaureate Degree: Evaluation Study among Practicing Pharmacists in Sudan.</u>

Abuabker Elbur *, Yousif MA. Elbur Al, Bin Shahna M, Izham MI, Elmustafa MO, Abdoon S. Ibrahim M. (pp. 516-521)

PHARMACEUTICAL CHEMISTRY

Anti-Diabetic Activity of Aqueous and Methanolic Extract of Abutilon Muticum

Girendra Kumar Gautam*¹, G. Vidhyasagar², S. C. Dwivedi³ and Sumeet Dwivedi⁴ (pp. 522-526)

Screening Angiotensin Converting Enzyme (ACE) Inhibitor Activity of Antihypertensive Medicinal Plants from Indonesia

Aprilita Rinayanti 1*, Maksum Radji², Abdul Mun'im ²and F.D. Suyatna³ (pp. 527-532)

All rights reserved, Copyright © 2010-2013 International Journal of Pharmacy Teaching & Practices ® DRUNPP Association of SARAJEVO & HERZEGOVINA, BOSNIA

The Effect of Regular Human Insulin and Glulisine Insulin on Blood Glucosa Concentration in Diabetic Nephropathy Patients with Hyperglycemia

^{1*}Budi Suprapti, ²Agung Pranoto, ¹Ardian Avrilena Mp., ¹Sumarno, ¹Samirah, ¹Wenny Putri Nilamsari

¹Clinical Pharmacy Department, Faculty of Pharmacy Airlangga University
Surabaya Indonesia, ²Internal Medicine Department, Dr.Soetomo Hospital, Surabaya Indonesia

Research Article

Please cite this paper as: ¹Budi Suprapti, ²Agung Pranoto, ¹Ardian Avrilena Mp., ¹Sumarno, ¹Samirah, ¹Wenny Putri Nilamsari. The Effect of Regular Human Insulin and Glulisine Insulin on Blood Glucosa Concentration in Diabetic Nephropathy Patients with Hyperglycemia. IJPTP, 2013, 4(1), 492-498.

Corresponding Author:

Dr. Budi Suprapti, Apt., MSi

Clinical Pharmacy Department

Faculty of Pharmacy Airlangga University

Campus B Jl. Darmawangsa Dalam, Surabaya, Indonesia

Office phone: +62-031-5033710 Fax number: +62-031-5020514 Mobile: +62-08155086694 Email: budiprapti@yahoo.co.id

Abstract

Objectives: This study was done to compare the effect of RHI 15 minutes before meal and glulisine insulin on blood glucose (BG) achievement and frequency of hypoglycemia in hospitalized Diabetic Nephropathy (DN) patients with hyperglycemia.

Method: Subjects were hospitalized DN patient with inclusion criteria: man/woman with DN stage 3-5 with or without hemodyalisis, 18-65 year old, BMI 18-35 kg/m2, glucose concentration within 200-400 mg/dl, provide written informed consent. Subject randomly divided into RHI and glulisine group. RHI was given 15 minutes before meal and glulisine insulin given 2 minutes before meal. Every subject was examined for preprandial BG (morning, afternoon, and night), 2 hour postprandial BG (morning, afternoon, and night) and bedtime BG concentration for three sequential observation, 24 hours each. Analysis BG data was done to see BG target achievement based on American Diabetes Association (ADA) target.

Result: From the total samples 30 patients (RHI: n=15; insulin glulisine: n=15) the results showed that on 1^{st} observation, preprandial, 2 hour post prandial, and bedtime BG had not reached ADA target. However, on the 2^{nd} and 3^{rd} observation, 2hpp blood glucose of both group had reached ADA target, but preprandial and bedtime still had not reached ADA target, the achievement less than 50% patients. The target achievement of preprandial, 2hPP and bedtime BG between RHI and glulisine insulin group was not significantly different. During study, there was no incidence or risk of hypoglycemia in both groups.

Conclusion: There was not significantly different in preprandial, 2hPP and bedtime glucose achievement between group RHI 15 minutes before meal and group glulisine insulin. There was no incidence or risk of hypoglycemia in both groups.

Keywords: Diabetes Mellitus, Diabetic Nephropathy, Regular Human Insulin, Glulisine Insuline, Blood Glucose, Hypoglycemia

Introduction

Diabetic nephropathy (DN) is a kidney disorder such as the condition of kidney failure caused by diabetes mellitus (DM). DN is defined as a clinical syndrome characterized by persistent albuminuria (> 300 mg/24 hours or> 200 mcg / min) at least in two measurements within 3-6 months ^{1, 2}. DN clinical criteria are defined if there are persistent albuminuria, duration of diabetes more than 10 years, suffering from DN without any disease in the kidney and renal tract. DN is associated with increase of blood pressure and decrease of glomerular filtration rate (GFR) ³.

Glycemic control is the most important management to prevent and treat DN. Glycemic control also reduces the risk of macrovascular and microvascular complications in other organs. Poor glycemic control will accelerate loss of renal function in DN ⁴.

Decrease of renal excretion causing DN patients are contraindicated a lot of oral antidiabetic (OAD) or they require dose adjustment ⁵. It also causes decrease of insulinase which will extend the half-life of insulin, thereby increase insulin concentration in the systemic circulation and then causes the DN patients at greater risk of hypoglycemia. Therefore, dose titration using insulin is easier than using OAD, particularly insulin bolus given at mealtime (prandial insulin) ⁶. Among all types of insulin, regular human insulin (RHI) and insulin glulisine are most often used.

International Journal of Pharmacy Teaching & Practices 2013, Vol.4, Issue 1, 492-498.

Most of RHI is in hexamer complexes (6 insulin molecules) and in smaller proportion as monomers and dimers. When injected subcutaneously, RHI needs a lot of time to dissociate into dimers and monomers before it is absorbed into the systemic circulation, therefore RHI has onset of action around 30 to 60 minutes. RHI reach peak concentration at 2.5 to 5 hours after administration and has duration of action 6-8 hours. All of those pharmacokinetic profiles make RHI need at least 30-60 minutes to work. In addition, RHI may cause post-prandial hyperglycemia and then followed by hypoglycemia if there is no meal at 3-4 hours after subcutaneous injection ^{7,8,9,10}.

At Dr. Soetomo Hospital RHI has been given to patients 15-30 minutes before meal. Giving RHI 30 minutes before eating will prevent increase of postprandial glucose concentration. While, if it is injected 15 minutes before meal, it will lead to postprandial hyperglycemia since onset of action has not been achieved. and will cause hypoglycemia at 4-8 hours after injection of RHI ^{6,7,11}.

Insulin glulisine is an endogenous insulin analogue that is modified by replacing the asparagine into lysine at position B3 and lysine to glutamic acid at position B29 which increases the solubility of insulin glulisine at physiological pH 10,12. Compared with RHI, glulisine insulin absorption after subcutaneous injection is faster (10-15 minutes) than that of RHI. Moreover, peak effect of glulisine insulin is reached more quickly (<1 hour) and duration of action is shorter (4-6 hours) than those of RHI $^{10,\,13}$. Pharmacokinetic profile of glulisine insulin is more similar to physiological insulin than those of RHI. In addition, the onset of action of insulin glulisine which is faster than that of RHI will make patients more convenient since they shouldn't wait for 60 minutes before taking meal $^{10, \ 14, \ 15}$. The duration of action of glulisine insulin is about 4 hours and it is not dose-dependent, while RHI has longer duration of action when given in larger doses. Thereby, glulisine insulin is more beneficial than RHI as glulisine insulin has a lower risk of hypoglycemia. Several studies showed that glulisine insulin was as effective as RHI, even there was one study that showed glulisine insulin was more effective than that of RHI in decreasing HbA1c 10.

Based on that background, we will conduct an observational cross-sectional study comparing the effect of RHI given 15 minutes and glulisine insulin given 2 minutes before meal on blood glucose concentration and frequency of hypoglycemia in hospitalized DN patients with hyperglycemia.

Material and Method

This study was randomized control trial to compare BG concentration and target achievement of RHI and glulisine insulin in hospitalized ND patients with hyperglycemia at Internal Medicine Department, Dr. Soetomo Hospital, Surabaya Indonesia and the research design was approved by Ethic Committee. Inclusion criteria were man/woman with DN stage 3-5 with or without hemodyalisis, 18-65 years old, BMI 18-35 kg/m2, glucose concentration within 200-400 mg/dl, provide written informed consent. Patients who have other

comorbids (for instance: stroke, chronic heart failure, acute myocardial infarction (AMI)) hiperosmolar, ketoacidosis diabetic, sepsis, pregnant) are excluded. Dropped out criteria were patients who die or decide to finish therapy before 3 sequential observation, suffer from severe hypoglycemia causing withdrawal of insulin, suffer from hypersensitive, and decide to resign from study.

Subject randomly divided into RHI and glulisine group. RHI was given 15 minutes before meal and glulisine insulin given 2 minutes before meal. Insulin dose given was adjusted in accordance with CBG level. Patients who have CBG level in the range 200-300 mg / dL received maintenance dose 3x4 UI daily, while patients in the range of 300-400 mg / dL received 3x6 UI daily. In the time course of observation, insulin dose will be adjusted, dose escalation performed if the patient does not respond to previous insulin dose, whereas dose reduction was done if patients blood glucose had achieved the target and to avoid the risk of hypoglycemia. Every subject was examined for preprandial BG (morning, afternoon, and night), 2 hour postprandial BG (morning, afternoon, and night) and bedtime BG concentration for three sequential observation, 24 hours each. Blood glucose was assayed by glucostick.

Analysis was done to compare (1) target glucose achievement recommended by ADA including preprandial, 2 hour postprandial and bedtime between group receiving glulisine insulin 2 minutes before meal and group receiving RHI 15 minutes before meal, (2) the incidence of hypoglycemia and hypoglycemia risk between groups.

Results

There were 32 patients meeting the inclusion criteria obtained (RHI: n = 16; insulin glulisine: n = 16) but two patients drop out (one patient in RHI group because of hematemesis that caused hypoglycemia; one patients in insulin glulisine group because of the forced discharge/suboptimal discharge). Therefore, total samples were 30 patients (RHI: n = 15; insulin glulisine: n = 15). Patient demographic data of both groups are relatively similar either in age, BMI and the degree of ND (Table 1).

At admission, casual blood glucose (CBG) level (Table 2) was examined. Besides being used to determine the maintenance dose of insulin, the initial casual plasma glucose (CBG) levels were also analyzed to see the homogeneity of the distribution of the initial CBG levels between groups to avoid bias. Test of independent sample t-test showed no

International Journal of Pharmacy Teaching & Practices 2013, Vol.4, Issue 1, 492-498.

significant difference in the distribution of initial CBG level between groups (p = 0.590).

Table 1 Patient demographic data of RHI group and glulisine insulin group

Demographic data		RHI Group Glulisine insulin g n = 15 n = 15 Number of Number of Patients (%) (%)	
Sex			Tuble 3
•	Male	5 (33.33)	6 (40,00)
•	Female	10 (66.67)	9 (60,00)
Age			
•	30-39 year	0	1 (6.66)
•	40-49 year	6 (40,00)	4 (26.67)
•	50-59 year	6 (40,00)	6 (40,00)
•	60-65 year	1 (20,00)	4 (26.67)
BMI (kg	/m²)		
•	18-20	0	1 (6.67)
•	20-25	14 (93.33)	11 (73.33)
•	25-30	1 (6.67)	3 (20,00)
Staging			
•	DN III	3 (20,00)	4 (26.67)
•	DN IV	5 (33.33)	5 (33.33)
•	DN V	7(46.67)	5 (40,00)

Three series of BG observations were revealed in observations 1, 2, and 3. Mean Blood Glucose (BG) for preprandial, postprandial and bed time in RHI and Glulisine insulin group at observation 1, 2 and 3 with its statistic analysis listed in Table 3

Table 2 Initial casual blood glucosa (CBG) level at admission in RHI group and Glulisine insulin

group)	Verenius de la companya de la compan
Initial CBG level	RHI Group (n = 15) Number of Patients (%)	Glulisine insulin group (n = 15) Number of Patients (%)
200-219	4 (26.67)	4 (26.67)
220-239	3 (20,00)	1 (6.67)
240-259	6 (40,00)	5 (33.33)
260-279	2 (13.33)	4 (26.67)
>280	1 (6,67)	1 (6,67)
Mean initial CBG level	244.87 ± 24.77	87 ± 34.67

Table 4 shows comparison target achievement between 2hPP BG morning, noon and night on the observation 1,2 and 3 and its statistical analysis (chi square) for inter - intra group of RHI and glulisine. Comparison target achievement of preprandial and bed time BG in RHI group and glulisine group listed in Table 5 and 6, respectively.

Discussion

In this study RHI and glulisine insulin were administered by subcutaneous injection, were carried out entirely on the arm to avoid the variability of insulin absorption from the injection site. Subcutaneous injection in the arm gives the moderately absorption rate, slower than the abdomen, but faster than the hips and thighs ^{10, 16}.

Mean Blood Glucose (BG) in RHI and Glulisine insulin groups at observation 1, 2 and 3 $\,$

Table 3: Mean Blood Glucose (BG) in RHI and Glulisine insulin g observation 1, 2 and 3

Rload Glucase (ma/dl)

OBSERVATION

1

Morning 176,50 ± 165,10 ± 0,486 preprandial BG 28,85 41,69 0,771 BG 36,64 63,30 0,771 BG 36,64 63,30 0,614 preprandial BG 43,94 41,63 0,614 preprandial BG 43,94 41,63 0,594 Noon 2hPP BG 174,13 ± 205,71 ± 0,120 S1,73 54,30 0,594 preprandial BG 37,43 56,99 Night 2hPP BG 191,13 ± 197,60 ± 0,742 46,10 59,73 59,64 Bedtime BG 181,73 ± 187,87 ± 0,750 OBSERVATION 2 140,73 ± 0,170 Preprandial BG 44,34 21,53 0,170 Morning 2hPP BG 33,32 27,27 0,279 Preprandial BG 26,02 20,20 Noon 2hPP BG 33,32 27,27 0,584 Preprandial BG 37,51 <th></th> <th colspan="3">Blood Glucose (mg/dL)</th>		Blood Glucose (mg/dL)		
Morning 176,50 ± 165,10 ± 0,486 preprandial BG 28,85 41,69 Morning 2hPP 182,08 ± 188,00 ± 0,771 BG 36,64 63,30 Noon 178,56 ± 166,83 ± 0,614 preprandial BG 43,94 41,63 Noon 2hPP BG 174,13 ± 205,71 ± 0,120 51,73 54,30 Night 187,27 ± 198,15 ± 0,594 preprandial BG 37,43 56,99 Night 2hPP BG 46,10 59,73 Bedtime BG 44,34 21,53 Morning 158,67 ± 140,73 ± 0,750 preprandial BG 44,34 21,53 Morning 2hPP 147,80 ± 142,20 ± 0,603 Morning 2hPP 147,80 ± 153,27 ± 0,279 preprandial BG 26,02 20,20 Noon 2hPP BG 37,51 34,33 Night 2hPP BG 37,32 27,34 Bedtime BG 30,61 14,58 Morning 2hPP 141,53 ± 156,50 ± 0,087 preprandial BG 30,61 14,58 Morning 2hPP 141,53 ± 144,80 ± 0,709 BG 27,90 18,56 Noon 144,67 ± 146,07 ± 0,891 preprandial BG 33,50 20,28 Noon 2hPP BG 152,22 27,03 Night 141,33 ± 149,20 ± 0,433 Bedtime BG 32,48 20,32 Night 2hPP BG 32,48 20,32 Night 2hPP BG 32,48 20,32 Night 141,53 ± 144,50 ± 0,479 Breprandial BG 32,48 20,32 Night 2hPP BG 142,57 ± 136,87 ± 0,462 25,22 27,03 Night 141,33 ± 149,20 ± 0,433 Bedtime BG 32,48 20,32 Night 2hPP BG 32,09 21,31 Bedtime BG 147,54 ± 141,33 ± 0,479		DUI Croum	Glulisine	P
preprandial BG 28,85 41,69 Morning 2hPP 182,08 ± 188,00 ± 0,771 BG 36,64 63,30 Noon Noon 2hPP BG 174,13 ± 205,71 ± 0,120 Night 187,27 ± 198,15 ± 0,594 preprandial BG 37,43 56,99 0,594 Night 2hPP BG 191,13 ± 197,60 ± 0,742 46,10 59,73 181,73 ± 187,87 ± 0,750 Bedtime BG 181,73 ± 187,87 ± 0,750 OBSERVATION 2 2 Morning 158,67 ± 140,73 ± 0,170 preprandial BG 44,34 21,53 Morning 2hPP 147,80 ± 142,20 ± 0,603 BG 35,86 20,34 Noon 162,67 ± 153,27 ± 0,279 preprandial BG 26,02 20,20 20,20 20,20 20,20 Noon 2hPP BG 156,40 ± 153,20 ± 0,776 33,32 27,27 27,70		Kni Group	Group	
Morning 2hPP 182,08 ± 188,00 ± 0,771 BG 36,64 63,30 Non Noon 178,56 ± 166,83 ± 0,614 preprandial BG 43,94 41,63 Noon 2hPP BG 174,13 ± 205,71 ± 0,120 51,73 54,30 56,99 Night 187,27 ± 198,15 ± 0,594 preprandial BG 37,43 56,99 0,742 Night 2hPP BG 191,13 ± 197,60 ± 0,742 46,10 59,73 8 9 Bedtime BG 35,60 59,64 OBSERVATION 2 140,73 ± 0,750 A4,34 21,53 140,73 ± 0,400 Morning 2hPP 147,80 ± 142,20 ± 0,603 BG 35,86 20,34 20,32 Noon 2hPP BG 35,86 20,34 20,20 Noon 2hPP BG 156,40 ± 153,20 ± 0,776 33,32 27,27 1,76 1,43,33	Morning	176,50 ±	165,10 ±	0,486
BG 36,64 63,30 Noon 178,56 ± 166,83 ± 0,614 preprandial BG 43,94 41,63 Noon 2hPP BG 174,13 ± 205,71 ± 0,120 Si,73 54,30 56,99 Night 187,27 ± 198,15 ± 0,594 preprandial BG 37,43 56,99 0,742 Night 2hPP BG 46,10 59,73 59,64 Bedtime BG 181,73 ± 187,87 ± 0,750 Bedtime BG 43,60 59,64 59,64 OBSERVATION 2 0,750 BG 35,86 20,34 0,750 BG 35,86 20,34 0,603 BG 35,86 20,34 0,603 Noon 162,67 ± 153,27 ± 0,279 preprandial BG 26,02 20,20 0,00 Noon 2hPP BG 37,51 34,33 131,47 ± 158,14 ± 0,045 Night 2hPP BG 37,51 34,33 143,33	preprandial BG	28,85	41,69	
Noon 178,56 ± 166,83 ± 0,614 preprandial BG 43,94 41,63 Noon 2hPP BG 174,13 ± 205,71 ± 0,120 51,73 54,30 Night 187,27 ± 198,15 ± 0,594 preprandial BG 37,43 56,99 Night 2hPP BG 46,10 59,73 Bedtime BG 43,60 59,64 OBSERVATION 2	Morning 2hPP	182,08 ±	188,00 ±	0,771
Noon 2hPP BG	BG	36,64	63,30	
Noon 2hPP BG 174,13 ± 51,73 205,71 ± 54,30 0,120 Night preprandial BG 37,43 56,99 0,742 Night 2hPP BG 191,13 ± 197,60 ± 46,10 59,73 0,750 Bedtime BG 181,73 ± 187,87 ± 0,750 0,750 OBSERVATION 2 2 0,170 Morning 158,67 ± 140,73 ± 0,170 0,170 preprandial BG 44,34 21,53 Morning 2hPP 147,80 ± 142,20 ± 0,603 0,603 BG 35,86 20,34 Noon 162,67 ± 153,27 ± 0,279 0,279 preprandial BG 26,02 20,20 Noon 2hPP BG 33,32 27,27 Night 160,93 ± 153,67 ± 0,584 156,40 ± 153,20 ± 0,776 37,32 27,34 Preprandial BG 37,51 34,33 Night 2hPP BG 37,32 27,34 Bedtime BG 137,79 ± 156,50 ± 0,087 28,25 OBSERVATION 3 3 Morning 151,40 ± 154,13 ± 0,757 preprandial BG 30,61 14,58 Morning 2hPP 141,53 ± 144,80 ± 0,709 BG 27,90 18,56 Noon 2hPP BG 25,22	Noon	178,56 ±	166,83 ±	0,614
Night 187,27 ± 198,15 ± 0,594 preprandial BG 37,43 56,99 Night 2hPP BG 46,10 59,73 Bedtime BG 181,73 ± 187,87 ± 0,750 43,60 59,64 OBSERVATION 2	preprandial BG	43,94	41,63	
Night 187,27 ± 198,15 ± 0,594 preprandial BG 37,43 56,99 Night 2hPP BG 46,10 59,73 Bedtime BG 181,73 ± 187,87 ± 0,750 43,60 59,64 OBSERVATION 2	Name 2500 DC	174,13 ±	205,71 ±	0,120
Preprandial BG 37,43 56,99 Night 2hPP BG 191,13 ± 197,60 ± 0,742 46,10 59,73 Bedtime BG 181,73 ± 187,87 ± 0,750 43,60 59,64 OBSERVATION 2 Worning 158,67 ± 140,73 ± 0,170 preprandial BG 44,34 21,53 Morning 2hPP 147,80 ± 142,20 ± 0,603 BG 35,86 20,34 Noon 162,67 ± 153,27 ± 0,279 preprandial BG 26,02 20,20 Noon 2hPP BG 156,40 ± 153,20 ± 0,776 33,32 27,27 Night 160,93 ± 153,67 ± 0,584 preprandial BG 37,51 34,33 Night 2hPP BG 131,47 ± 158,14 ± 0,045 37,32 27,34 Bedtime BG 137,79 ± 156,50 ± 0,087 OBSERVATION 3 Morning 151,40 ± 154,13 ± 0,757 preprandial BG 30,61 14,58 Morning 2hPP 141,53 ± 144,80 ± 0,709 BG 27,90 18,56 Noon 2hPP BG 142,57 ± 136,87 ± 0,462 25,22	NOON ZNPP BG	51,73	54,30	
Night 2hPP BG 46,10 59,73 Bedtime BG 181,73 ± 187,87 ± 0,750 59,64 OBSERVATION 2 Morning 158,67 ± 140,73 ± 0,170 preprandial BG 44,34 21,53 Morning 2hPP 147,80 ± 142,20 ± 0,603 BG 35,86 20,34 Noon 162,67 ± 153,27 ± 0,279 preprandial BG 26,02 20,20 Noon 2hPP BG 156,40 ± 153,20 ± 0,776 33,32 27,27 Night 160,93 ± 153,67 ± 0,584 preprandial BG 37,51 34,33 Night 2hPP BG 131,47 ± 158,14 ± 0,045 37,32 27,34 Bedtime BG 137,79 ± 156,50 ± 0,087 28,25 27,50 OBSERVATION 3 Morning 151,40 ± 154,13 ± 0,757 preprandial BG 30,61 14,58 Morning 2hPP 141,53 ± 144,80 ± 0,709 BG 27,90 18,56 Noon 144,67 ± 146,07 ± 0,891 preprandial BG 33,50 20,28 Noon 2hPP BG 142,57 ± 136,87 ± 0,462 25,22 27,03 Night 141,33 ± 149,20 ± 0,433 preprandial BG 32,48 20,32 Night 2hPP BG 32,09 21,31 Bedtime BG 147,54 ± 136,93 ± 0,654 32,09 21,31 Bedtime BG	Night	187,27 ±	198,15 ±	0,594
Night 2hPP BG	preprandial BG	37,43	56,99	
Night 2nPP BG	N:-L+ 2LDD DC	191,13 ±	197,60 ±	0,742
Morning 158,67 ± 140,73 ± 0,170 preprandial BG 44,34 21,53 Morning 2hPP 147,80 ± 153,27 ± 0,279 preprandial BG 26,02 20,20 Noon 2hPP BG 33,32 27,27 Night 160,93 ± 153,67 ± 0,045 28,25 27,50 Noon 2hPP BG 37,32 27,34 Sedtime BG 28,25 27,50 Noon 2hPP BG 30,61 14,58 Morning 2hPP 141,53 ± 144,80 ± 0,709 BG 27,90 18,56 Noon 144,67 ± 146,07 ± 0,891 preprandial BG 33,50 20,28 Noon 2hPP BG 25,22 27,03 Night 141,33 ± 149,20 ± 0,433 preprandial BG 33,50 20,28 Night 141,33 ± 149,20 ± 0,433 preprandial BG 32,48 20,32 Night 2hPP BG 32,09 21,31 Bedtime BG 32,0	Night ZhPP BG	46,10	59,73	
Morning 158,67 ± 140,73 ± 0,170 preprandial BG 44,34 21,53 Morning 2hPP 147,80 ± 142,20 ± 0,603 BG 35,86 20,34 Noon 162,67 ± 153,27 ± 0,279 preprandial BG 26,02 20,20 Noon 2hPP BG 33,32 27,27 Night 160,93 ± 153,67 ± 0,584 preprandial BG 37,51 34,33 Night 2hPP BG 37,32 27,34 Sedtime BG 28,25 27,50 OBSERVATION 3 Morning 151,40 ± 154,13 ± 0,757 preprandial BG 30,61 14,58 Morning 2hPP 141,53 ± 144,80 ± 0,709 BG 27,90 18,56 Noon 144,67 ± 146,07 ± 0,891 preprandial BG 33,48 20,32 Night 141,33 ± 149,20 ± 0,433 preprandial BG 32,48 20,32 Night 2hPP BG 32,09 21,31 Redtime BG 22,09 21,31 Redtime BG 32,09 21,31 Redtime BG 32,09 21,31 Redtime BG 32,09 21,31 Redtime BG 32,09 21,31 Redtime BG 147,54 ± 141,33 ± 0,479	Dadkima DC	181,73 ±	187,87 ±	0,750
Morning 158,67 ± 140,73 ± 0,170 preprandial BG 44,34 21,53 Morning 2hPP 147,80 ± 142,20 ± 0,603 BG 35,86 20,34 Noon 162,67 ± 153,27 ± 0,279 preprandial BG 26,02 20,20 Noon 2hPP BG 33,32 27,27 Night 160,93 ± 153,67 ± 0,584 preprandial BG 37,51 34,33 Night 2hPP BG 37,32 27,34 Sedtime BG 28,25 27,50 OBSERVATION 3 Morning 151,40 ± 154,13 ± 0,757 preprandial BG 30,61 14,58 Morning 2hPP 141,53 ± 144,80 ± 0,709 BG 27,90 18,56 Noon 144,67 ± 146,07 ± 0,891 preprandial BG 33,50 20,28 Noon 2hPP BG 12,92 27,03 Night 141,33 ± 149,20 ± 0,433 preprandial BG 32,48 20,32 Night 2hPP BG 32,09 21,31 Bedtime BG 32,09 21,31 Bedtime BG 32,09 21,31 Bedtime BG 147,54 ± 141,33 ± 0,479 Bedtime BG 32,09 21,31 Bedtime BG 147,54 ± 141,33 ± 0,479	Beatime BG	43,60	59,64	
Morning 158,67 ± 140,73 ± 0,170 preprandial BG 44,34 21,53 Morning 2hPP 147,80 ± 142,20 ± 0,603 BG 35,86 20,34 Noon 162,67 ± 153,27 ± 0,279 preprandial BG 26,02 20,20 Noon 2hPP BG 156,40 ± 153,20 ± 0,776 33,32 27,27 0,584 preprandial BG 37,51 34,33 34,33 Night 2hPP BG 131,47 ± 158,14 ± 0,045 37,32 27,34 156,50 ± 0,087 Bedtime BG 137,79 ± 156,50 ± 0,087 DSERVATION 3 30,61 14,58 Morning 151,40 ± 154,13 ± 0,757 preprandial BG 30,61 14,58 Morning 2hPP 141,53 ± 144,80 ± 0,709 BG 27,90 18,56 Noon 144,67 ± 146,07 ± 0,891 preprandial BG 33,50 20,28 Noon 2hPP BG 25,22 27,03	OBSERVATION			
preprandial BG 44,34 21,53 Morning 2hPP 147,80 ± 142,20 ± 0,603 BG 35,86 20,34 Noon Noon 162,67 ± 153,27 ± 0,279 preprandial BG 26,02 20,20 20,77 Noon 2hPP BG 156,40 ± 153,20 ± 0,776 33,32 27,27 0,584 preprandial BG 37,51 34,33 Night 2hPP BG 131,47 ± 158,14 ± 0,045 37,32 27,34 37,32 27,34 Bedtime BG 137,79 ± 156,50 ± 0,087 DSERVATION 3 30,61 14,58 Morning 151,40 ± 154,13 ± 0,757 preprandial BG 30,61 14,58 Morning 2hPP 141,53 ± 144,80 ± 0,709 BG 27,90 18,56 Noon 144,67 ± 146,07 ± 0,891 preprandial BG 33,50 20,28 Noon 2hPP BG 142,57 ± <td>2</td> <td></td> <td></td> <td></td>	2			
preprandial BG 44,34 21,53 Morning 2hPP 147,80 ± 142,20 ± 0,603 BG 35,86 20,34 20,29 Noon 162,67 ± 153,27 ± 0,279 preprandial BG 26,02 20,20 20,20 Noon 2hPP BG 156,40 ± 153,20 ± 0,776 33,32 27,27 0,584 preprandial BG 37,51 34,33 Night 2hPP BG 131,47 ± 158,14 ± 0,045 37,32 27,34 0,087 Bedtime BG 137,79 ± 156,50 ± 0,087 BERVATION 3 30,61 14,58 Morning 151,40 ± 154,13 ± 0,757 preprandial BG 30,61 14,58 Morning 2hPP 141,53 ± 144,80 ± 0,709 BG 27,90 18,56 Noon 144,67 ± 146,07 ± 0,891 preprandial BG 33,50 20,28 Noon 2hPP BG 142,57 ± 136,87 ±<	Morning	158,67 ±	140,73 ±	0,170
BG 35,86 20,34 Noon 162,67 ± 153,27 ± 0,279 preprandial BG 26,02 20,20 Noon 2hPP BG 156,40 ± 153,20 ± 0,776 33,32 27,27 0,584 Night 160,93 ± 153,67 ± 0,584 preprandial BG 37,51 34,33 34,33 Night 2hPP BG 131,47 ± 158,14 ± 0,045 37,32 27,34 37,32 27,34 Bedtime BG 137,79 ± 156,50 ± 0,087 28,25 27,50 0 0 OBSERVATION 3 30,61 14,58 0,757 preprandial BG 30,61 14,58 0,757 Morning 2hPP 141,53 ± 144,80 ± 0,709 BG 27,90 18,56 0,099 Noon 2hPP BG 33,50 20,28 Noon 2hPP BG 142,57 ± 136,87 ± 0,462 25,22 27,03 0,433 preprandial BG 32,48 20,32 Night 2hPP BG <	preprandial BG	44,34		
Noon 162,67 ± 153,27 ± 0,279 preprandial BG 26,02 20,20 0,776 Noon 2hPP BG 156,40 ± 153,20 ± 0,776 33,32 27,27 0,584 Night 160,93 ± 153,67 ± 0,584 preprandial BG 37,51 34,33 0,045 Night 2hPP BG 131,47 ± 158,14 ± 0,045 37,32 27,34 0,087 Bedtime BG 137,79 ± 156,50 ± 0,087 28,25 27,50 0 0 OBSERVATION 3 30,61 14,58 Morning 151,40 ± 154,13 ± 0,757 preprandial BG 30,61 14,58 0,709 BG 27,90 18,56 0 Noon 144,67 ± 146,07 ± 0,891 preprandial BG 33,50 20,28 Noon 2hPP BG 142,57 ± 136,87 ± 0,462 25,22 27,03 Night 141,33 ±	Morning 2hPP	147,80 ±	142,20 ±	0,603
Noon 162,67 ± 153,27 ± 0,279 preprandial BG 26,02 20,20 0,776 Noon 2hPP BG 156,40 ± 153,20 ± 0,776 33,32 27,27 0,584 Night 160,93 ± 153,67 ± 0,584 preprandial BG 37,51 34,33 34,33 Night 2hPP BG 131,47 ± 158,14 ± 0,045 37,32 27,34 37,32 27,34 Bedtime BG 137,79 ± 156,50 ± 0,087 28,25 27,50 0 0 OBSERVATION 3 30,61 14,58 0,757 preprandial BG 30,61 14,58 0,757 preprandial BG 30,61 14,80 ± 0,709 BG 27,90 18,56 0 Noon 144,67 ± 146,07 ± 0,891 preprandial BG 33,50 20,28 Noon 2hPP BG 142,57 ± 136,87 ± 0,462 25,22 27,0	BG	35,86	20,34	
preprandial BG 26,02 20,20 Noon 2hPP BG 156,40 ± 153,20 ± 0,776 33,32 27,27 0,584 Night 160,93 ± 153,67 ± 0,584 preprandial BG 37,51 34,33 Night 2hPP BG 131,47 ± 158,14 ± 0,045 37,32 27,34 156,50 ± 0,087 Bedtime BG 137,79 ± 156,50 ± 0,087 28,25 27,50 0 0 OBSERVATION 3 30,61 14,58 0,757 preprandial BG 30,61 14,58 0,757 preprandial BG 30,61 14,80 ± 0,709 BG 27,90 18,56 0,099 Noon 144,67 ± 146,07 ± 0,891 preprandial BG 33,50 20,28 Noon 2hPP BG 142,57 ± 136,87 ± 0,462 25,22 27,03 Night 141,33 ± 149,20 ± 0,433	Noon	162,67 ±		0,279
Noon 2NPP BG 33,32 7,27 Night 160,93 ± 153,67 ± 0,584 preprandial BG 37,51 34,33 Night 2hPP BG 37,32 27,34 Bedtime BG 131,47 ± 158,14 ± 0,045 37,32 27,34 Bedtime BG 137,79 ± 156,50 ± 0,087 28,25 27,50 OBSERVATION 3 Morning 151,40 ± 154,13 ± 0,757 preprandial BG 30,61 14,58 Morning 2hPP 141,53 ± 144,80 ± 0,709 BG 27,90 18,56 Noon 144,67 ± 146,07 ± 0,891 preprandial BG 33,50 20,28 Noon 2hPP BG 142,57 ± 136,87 ± 0,462 25,22 27,03 Night 141,33 ± 149,20 ± 0,433 preprandial BG 32,48 20,32 Night 2hPP BG 32,09 21,31 Bedtime BG 147,54 ± 141,33 ± 0,479	preprandial BG	26,02		
Night 160,93 ± 153,67 ± 0,584 preprandial BG 37,51 34,33 Night 2hPP BG 131,47 ± 158,14 ± 0,045 37,32 27,34 Bedtime BG 137,79 ± 156,50 ± 0,087 28,25 27,50 OBSERVATION 3	Name of DD DC	156,40 ±	153,20 ±	0,776
preprandial BG 37,51 34,33 Night 2hPP BG 131,47 ± 158,14 ± 0,045 37,32 27,34 156,50 ± 0,087 Bedtime BG 137,79 ± 156,50 ± 0,087 28,25 27,50 27,50 OBSERVATION 3 30,61 154,13 ± 0,757 preprandial BG 30,61 14,58 0,709 BG 27,90 18,56 0,709 BG 27,90 18,56 0,891 Noon 144,67 ± 146,07 ± 0,891 preprandial BG 33,50 20,28 Noon 2hPP BG 142,57 ± 136,87 ± 0,462 25,22 27,03 Night 141,33 ± 149,20 ± 0,433 preprandial BG 32,48 20,32 Night 2hPP BG 141,54 ± 136,93 ± 0,654 32,09 21,31 147,54 ± 141,33 ± 0,479	Noon 2npp BG	33,32		
Night 2hPP BG	Night	160,93 ±	153,67 ±	0,584
Night 2nPP BG 37,32 27,34 Bedtime BG 137,79 ± 28,25 156,50 ± 27,50 0,087 OBSERVATION 3 Morning 151,40 ± 154,13 ± 0,757 preprandial BG 30,61 14,58 Morning 2hPP 141,53 ± 144,80 ± 0,709 0,709 BG 27,90 18,56 146,07 ± 0,891 Noon 144,67 ± 146,07 ± 0,891 142,57 ± 136,87 ± 0,462 preprandial BG 33,50 20,28 20,28 Night 141,33 ± 149,20 ± 0,433 0,462 preprandial BG 32,48 20,32 20,32 Night 2hPP BG 32,09 21,31 147,54 ± 136,93 ± 0,654 Bedtime BG 147,54 ± 141,33 ± 0,479	preprandial BG	37,51	34,33	
Bedtime BG 137,32 137,79 ± 156,50 ± 0,087 28,25 27,50 OBSERVATION 3 Morning 151,40 ± 154,13 ± 0,757 preprandial BG 30,61 14,58 Morning 2hPP 141,53 ± 144,80 ± 0,709 BG 27,90 18,56 Noon 144,67 ± 146,07 ± 0,891 preprandial BG 33,50 20,28 Noon 2hPP BG 142,57 ± 136,87 ± 0,462 25,22 27,03 Night 141,33 ± 149,20 ± 0,433 preprandial BG 32,48 20,32 Night 2hPP BG 32,09 21,31 Bedtime BG 147,54 ± 141,33 ± 0,479	Niel+ al-pp pc	131,47 ±	158,14 ±	0,045
28,25 27,50 OBSERVATION 3 Morning 151,40 ± 154,13 ± 0,757 preprandial BG 30,61 14,58 Morning 2hPP 141,53 ± 144,80 ± 0,709 BG 27,90 18,56 Noon 144,67 ± 146,07 ± 0,891 preprandial BG 33,50 20,28 Noon 2hPP BG 25,22 27,03 Night 141,33 ± 149,20 ± 0,433 preprandial BG 32,48 20,32 Night 2hPP BG 32,09 21,31 Bedtime BG 147,54 ± 141,33 ± 0,479	MBUL SULL PR	37,32	27,34	
DBSERVATION 3 Morning 151,40 ± 154,13 ± 0,757 preprandial BG 30,61 14,58 Morning 2hPP 141,53 ± 144,80 ± 0,709 BG 27,90 18,56 Noon 144,67 ± 146,07 ± 0,891 preprandial BG 33,50 20,28 Noon 2hPP BG 142,57 ± 136,87 ± 0,462 25,22 27,03 Night 141,33 ± 149,20 ± 0,433 preprandial BG 32,48 20,32 Night 2hPP BG 32,09 21,31 Bedtime BG 147,54 ± 141,33 ± 0,479	Padtima DC	137,79 ±	156,50 ±	0,087
Morning 151,40 ± 154,13 ± 0,757 preprandial BG 30,61 14,58 Morning 2hPP 141,53 ± 144,80 ± 0,709 BG 27,90 18,56 Noon 144,67 ± 146,07 ± 0,891 preprandial BG 33,50 20,28 Noon 2hPP BG 142,57 ± 136,87 ± 0,462 25,22 27,03 Night 141,33 ± 149,20 ± 0,433 preprandial BG 32,48 20,32 Night 2hPP BG 141,54 ± 136,93 ± 0,654 32,09 21,31 Bedtime BG 147,54 ± 141,33 ± 0,479	весите вс	28,25	27,50	
Morning 151,40 ± 154,13 ± 0,757 preprandial BG 30,61 14,58 144,80 ± 0,709 BG 27,90 18,56 0,891 Noon 144,67 ± 146,07 ± 0,891 preprandial BG 33,50 20,28 Noon 2hPP BG 142,57 ± 136,87 ± 0,462 25,22 27,03 Night 141,33 ± 149,20 ± 0,433 preprandial BG 32,48 20,32 Night 2hPP BG 141,54 ± 136,93 ± 0,654 32,09 21,31 Bedtime BG 147,54 ± 141,33 ± 0,479	OBSERVATION			
preprandial BG 30,61 14,58 Morning 2hPP 141,53 ± 144,80 ± 0,709 BG 27,90 18,56 Noon 144,67 ± 146,07 ± 0,891 preprandial BG 33,50 20,28 Noon 2hPP BG 142,57 ± 136,87 ± 0,462 25,22 27,03 Night 141,33 ± 149,20 ± 0,433 preprandial BG 32,48 20,32 Night 2hPP BG 141,54 ± 136,93 ± 0,654 32,09 21,31 Bedtime BG 147,54 ± 141,33 ± 0,479	3			
Morning 2hPP 141,53 ± 144,80 ± 0,709 BG 27,90 18,56 0,891 Noon 144,67 ± 146,07 ± 0,891 preprandial BG 33,50 20,28 Noon 2hPP BG 142,57 ± 136,87 ± 0,462 25,22 27,03 Night 141,33 ± 149,20 ± 0,433 preprandial BG 32,48 20,32 Night 2hPP BG 141,54 ± 136,93 ± 0,654 32,09 21,31 Bedtime BG 147,54 ± 141,33 ± 0,479	Morning	151,40 ±	154,13 ±	0,757
BG 27,90 18,56 Noon 144,67 ± 146,07 ± 0,891 preprandial BG 33,50 20,28 Noon 2hPP BG 142,57 ± 136,87 ± 0,462 25,22 27,03 Night 141,33 ± 149,20 ± 0,433 preprandial BG 32,48 20,32 Night 2hPP BG 141,54 ± 136,93 ± 0,654 32,09 21,31 Bedtime BG 147,54 ± 141,33 ± 0,479	preprandial BG	30,61	14,58	
Noon 144,67 ± 146,07 ± 0,891 preprandial BG 33,50 20,28 Noon 2hPP BG 142,57 ± 136,87 ± 0,462 25,22 27,03 Night 141,33 ± 149,20 ± 0,433 preprandial BG 32,48 20,32 Night 2hPP BG 141,54 ± 136,93 ± 0,654 32,09 21,31 Bedtime BG 147,54 ± 141,33 ± 0,479	Morning 2hPP	141,53 ±	144,80 ±	0,709
preprandial BG 33,50 20,28 Noon 2hPP BG 142,57 ± 136,87 ± 0,462 25,22 27,03 Night 141,33 ± 149,20 ± 0,433 preprandial BG 32,48 20,32 Night 2hPP BG 141,54 ± 136,93 ± 0,654 32,09 21,31 Bedtime BG 147,54 ± 141,33 ± 0,479	BG	27,90	18,56	
Noon 2hPP BG 142,57 ± 25,22 136,87 ± 27,03 0,462 Night 141,33 ± 149,20 ± 0,433 0,433 preprandial BG 32,48 20,32 20,32 Night 2hPP BG 141,54 ± 136,93 ± 0,654 32,09 21,31 Bedtime BG 147,54 ± 141,33 ± 0,479	Noon	144,67 ±	146,07 ±	0,891
Night 2hPP BG 25,22 27,03 Night 141,33 ± 149,20 ± 0,433 preprandial BG 32,48 20,32 Night 2hPP BG 141,54 ± 136,93 ± 0,654 32,09 21,31 Bedtime BG 147,54 ± 141,33 ± 0,479	preprandial BG	33,50	20,28	
Night 141,33 ± 149,20 ± 0,433 preprandial BG 32,48 20,32 Night 2hPP BG 141,54 ± 136,93 ± 0,654 32,09 21,31 Bedtime BG 147,54 ± 141,33 ± 0,479	Noon 2hDD BG	142,57 ±	136,87 ±	0,462
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	NOON ZIPP BO	25,22	27,03	
Night 2hPP BG 141,54 ± 136,93 ± 0,654 32,09 21,31 147,54 ± 141,33 ± 0,479	Night	141,33 ±	149,20 ±	0,433
32,09 21,31 Bedtime BG 147,54 ± 141,33 ± 0,479	preprandial BG	32,48	20,32	
32,09 21,31 Bedtime BG 147,54 ± 141,33 ± 0,479	Night 2hDD RG	141,54 ±	136,93 ±	0,654
Begume BG	MIGHT ZHEF DO	32,09	21,31	
25,79 19,89	Redtime RG	147,54 ±	141,33 ±	0,479
	Jedunie BO	25,79	19,89	

Insulin used in patients with DN are expected to control the 2hPPG, preprandial glucose, and bedtime glucose without causing hypoglycemia. Based on ADA, desired target levels of 2hPPG range from 70-179 mg/dL and target of preprandial and bed time glucose level range from 70-130 mg/dL ¹⁷.

Table 4 Comparison achievement 2hPP glucose level in RHI group and glulisine insulin groups

Obser	T	% target	% target 2hPP glucose ^(*)			
vation	Time	RHI	Glulisin	Intergr	Intra gro	up
		(%)	e (%)	oup	RHI	Glulisine
1	Morning	46,15	50,00	0,842		
	Noon	46,67	35,71	0,461	0.500	0.724
	Night	33,33	40,00	0,705	0,589	0,734
	Total	42,05	41,90	0,600		
2	Morning	86,67	100,00	0,143		
	Noon	66,67	93,33	0,068	0,355	0.581
	Night	80,00	92,86	0,512	0,333	0,381
	Total	77,78	95,40	0,048		
3	Morning	93,33	100,00	0,309		
	Noon	100,00	100,00		0,411	0,360
	Night	100,00	93,33	0,343		
	Total	97,78	97,78	0,947		
Total 2h glucose		72,54	78,36	0,367		
(*)	% tar of pa	atients who		the target o		om the number he number of
(**)		_				total patients ation (1,2,3)

Table 5 Comparison achievement preprandial glucose in RHI group and glulisine insulin group

Obse rvati on	time	%target preprandial glucose ^(*)		P value		
		RHI (%) Glulis (%)	Glulicino	Intergrou	Intra group	
				p	RHI	Glulisi ne
1	mornin g	0	20,00	0,136		
	noon night	11,11 0	33,33 0	0,292	0,29 9	0,115
	Total	3,33	13,79	0,149		
2	mornin g	33,33	26,67	0,690	0,18 9	0,659
	noon	6,67	13,33	0,543		
	night	20,00	20,00	1,000		
	Total	20,00	20,00	1,000		
3	mornin g	26,67	0	0,032	0,72 4	0,146
	noon	26,67	20,00	0,666		
	night	26,67	6,67	0,177		
	Total	26,67	8,89	0,047		
Total prepra glucos	ndial	18,33	14,29	0,414		

(*) % target achievement preprandial glucose obtained from the number of patients who achieved the target divided by the number of patients each observation

(**) % target achievement 2hPP total obtained from total patients who achieved the target divided by total observation Observation 1 results (Table 3) shows that only noon 2hpp mean BG levels of the RHI group reached the ADA target. There were no significant differences in morning, noon and night of preprandial, 2hpp and bedtime glucose level between insulin glulisine and RHI groups (p> 0.05). While observation 2 shows morning, noon, and night 2hpp mean BG levels both groups had reached the target. In contrast to 2hpp levels, mean of preprandial BG for all time and bedtime BG levels both groups did not reach the target. At observation 3 morning, noon and night 2hpp mean BG levels both groups reached the ADA target, but the mean levels of all preprandial BG levels both groups did not reach the target. There was no significantly difference of all glucose types (morning, noon and night 2hpp, preprandial, and bedtime BG) between RHI and insulin glulisine group (p>0.05).

Table 6 Comparison bedtime level in RHI group and

Observ	at Target be	Target bedtime glucose(*)		
ion	RHI (%)	Glulisine (%)	chi square	
1	13.33	20,0	0,624	
2	35,70	14,29	0,424	
3	30,77	26,67	0,811	
Total (*	*) 26,29	20.45	0,529	
(*)	% target achievement bedtime glucose obtained from the number of patients who achieved the target divided by the number of patients each observation			
(**)	% target achievement bedtime total			

obtained from total patients who achieved

the target divided by total observation

Table 4 shows comparison target achievement between 2hPP morning, noon and night on the observation 1,2 and 3 and its statistical analysis (chi square). There was an increase in the percentage of patients, observation 1 -3, who achieved the target. The percentage of total patients who achieved 2hpp target at observations 1, 2, and 3 for the RHI group.was 42.05%, 77.78% and 97.78% respectively, while, the insulin glulisine group were 41.90%, 95.40% and 97.78% respectively.

The percentage of patients who achieved 2hpp target at observation 1 was not significantly different in both groups (p = 0.600). At observation 2, the percentage of patients who achieved 2hpp target in the insulin glulisine group was higher than RHI group which were 95.40% vs. 77.78% (p = 0.048) and had similar achievement (97.78%) at observations 3 (p = 0.947).

Several studies showed that glulisine insulin is as effective as RHI, even there is one study that showed glulisine insulin is more effective in

International Journal of Pharmacy Teaching & Practices 2013, Vol.4, Issue 1, 492-498.

decreasing HbA1c levels ^{9, 10, 15}. Comparative clinical study of efficacy and safety of insulin glulisine and RHI (both combined with NPH insulin) conducted in patients with type 2 diabetes for 26 weeks showed there was a higher decrease in HbA1c levels in the glulisine insulin group than RHI group. That study also shows the results of self-monitoring blood glucose (SMBG) at 7 points which was lower in the glulisine insulin group than RHI group ¹¹. Results obtained from this study also showed that the 2hpp achievement in glulisine insulin group was better than RHI group, especially at observation 2, although not significantly different (p> 0.05).

RHI is in hexamer complex, thus when injected subcutaneously, RHI takes time for dissociating into dimers and monomers before it is absorbed into the systemic circulation, whereas insulin glulisine has been in monomer form. This slow dissociation of RHI causes slower absorption compared to insulin glulisine (30 min vs. 15 min) and when administered subcutaneously, RHI achieves peak time slower than insulin glulisine (2.5 - 5 hours vs. <1 hour). Thus. at 2 hour post meal, RHI has not reached the peak of action, resulting in postprandial hyperglycemia. That factor causes insulin glulisine is able to control postprandial glucose levels better than RHI ⁸, 9,10

Based on ADA, target of preprandial glucose level range from 70-130 mg / dL. The results (Table 5) shows at observation 1, insulin glulisine group reached the percentage of preprandial target higher than RHI group which were 17.78% vs. 3.70% (p = 0.249) respectively. But at observations 2 both group had similar achievement and at observation 3, group of insulin glulisine reached the percentage of reprandial target lower than RHI group which were 8.89% vs. 26,67 (p = 0.047). Overall, the percentage of preprandial glucose target was still low (less than 50%) and there was no significant difference between groups RHI and insulin glulisine group at observations 1, 2, and 3 (p = 0.414).

Bedtime glucose target in this study is the same as ADA recommendations, which range from 70-130 mg/dL. Table 5 showed at observation 1 group glulisine insulin reached the percentage of bedtime target higher than RHI group which were 20% vs. 13.33% (p = 0.624), respectively. However, at observations 2 and 3, group insulin glulisine reached the percentage of preprandial target lower than RHI group which were 14.29% vs. 35.7% (at observation 2) (p = 0.424) and 26.67% vs. 30.77% (at the observations 3) (p = 0.811). Overall there was no significant difference between RHI group and insulin glulisine group at observations 1, 2, and 3 (p = 0.529).

The duration of action of glulisine insulin is shorter than that of RHI (4-5 hours vs. 6-8 hours), no dose-dependent $^{8, 9, 10}$. This factor explain why insulin glulisine group achieved preprandial and bedtime glucose target lower than RHI did, although not significantly different (p> 0.05).

In this study frequency of hypoglycemia and the risk of hypoglycemia were observed. Patients at risk of hypoglycemia if preprandial glucose, 2hpp, and bedtime glucose between 6069 mg/dL. RHI is stated to have a greater risk of hypoglycemia because RHI has a peak time (2-5 hours) and a longer duration (6-8 hours) than glulisine insulin especially if patients do not take meal 3-4 hours after subcutaneous injection ^{8,9,10}.

The results showed, during study, there was no incidence of hypoglycemia or hypoglycemia risk in both groups. This research was conducted without the use of basal insulin. As discussed previously, there were poor achievements in the preprandial and bedtime BG levels in RHI group which were 18,33% and 26,29% respectively and in glulisine insulin group 14,29% and 20,45% respectively. The administration of bolus insulin (RHI or glulisine) was able to achieved 2hpp target according to ADA, but not for preprandial and bedtime glucose level. Therefore, it is recommended to add basal insulin in the management of therapy.

Conclusion

There was not significantly different in preprandial, 2hPP and bedtime glucose achievement between RHI group and glulisine insulin group, but with poor target achievement of preprandial and bedtime in both groups (less than 50%). There was no incidence of hypoglycemia or hypoglycemia risk in both groups.

References

- 1. Powers, A.C. Diabetes Mellitus. *In:*Kasper, D. L., Braunwald, E., Fauci, A. S., Hauser, S. L., Longo, D. L., and Jameson, J. L. (Eds.). **Harrison's Principles of Internal Medicine**, 17th Edition, New York: The McGraw–Hill Companies, Inc. ., 2008: 2275–2304.
- 2. Triplitt, C.L., Reasner C.A., Isley W.L. Diabetes Mellitus. *In*:Dipiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G., Posey, L.M. (Eds.). **Pharmacotherapy a Pathophisiologic Approach**, 7th Edition. New York: The McGraw–Hill Co., Inc. ., 2008: 1205–1241.
- 3. Vora, J.P., Chattington, P.D., Ibrahim, H. Clinical Manifestation and Natural History of Diabetic Nephropathy. *In:* Johnson, R.J., Feehally, J. (Eds.). **Comp Clin Nephrol**. 1999: 34.1–34.12.
- 4. Brownlee, M., Alello, L.P., Cooper, M.E., Vinik, A.I., Nesto, R.W., Boulton, A.J.M.. Complication of Diabetes Mellitus. *In:* Kronenberg, H.M., Melmed, S., Polonsky, K.S., Larsen, P.R. (Eds.). **Kronenberg:** Williams Textbook of Endocrinology, 11th Edition. Philadelphia: Elsevier, Inc., 2008: 1417–1431, 1443–1449.
- 5. Simonson, D.C. Insulin Resistance and Diabetes in Chronic Renal Disease. *In:* Singh, A.J., Williams, G.H. (Eds.). **Textbook of Nephro-Endocrinology**. Philadelphia: Elsevier, Inc. 2009: 385 409.

- International Journal of Pharmacy Teaching & Practices 2013, Vol.4, Issue 1, 492-498.
- 6. Duckworth, W.C., Bennet, R.G., Hamel, F.G. Insulin Degradation: Progress and Potential. **Endocrine Rev.** ,1998: 19(5): 608–624.
- 7. Wittlin, S.D., Woehrle, H.J., Gericah, J.E. Insulin Pharmacokinetics, in Leahy, J.L., Cefolu, W.T. Insulin Therapy. Marcel Dekker, Inc., New York; 1998: 73-85.
- 8. Garg, S.K., Ellis, S.L., Ulrich, H. Insulin Glulisine: a new rapid—acting insulin analogue for the treatment of diabetes. **Expertt Opin Pharmacother**; 2005: 6 (4): 643–651.
- 9. Becker, R.H.A., Frick, A.D.V. Clinical Pharmacotkinetics and Pharmacodynamics of Insulin Glulisine. **Clin Pharmacokinet**; 2005; 47 (1): 7–20.
- 10. Garnock–Jones, K.P., Plosker, G.L. Insulin Glulisine a Review of its Use in the Management of Diabetes Mellitus. **Drugs**; 2009; 69 (8): 1035–1057.
- 11. Dailey, G., Rosenstock, J., Moses, R.G., Ways, K. Insulin Glulisine Provides Improved Glycemic Control in Patients With Type 2 Diabetes. **Diab Care**; 2004; 27: 2363–2368.
- 12. Rolla, A. Pharmacokinetics and Pharmacodynamic Advantages of Insulin Analogues and Premixed Insulin Analogues Over Human Insulins: Impact on Efficacy and Safety. **The Am J Med**; 2008; 121: S9-S19.
- 13. Becker, R.H.A., Frick, A.D., Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glulisin. Clin Pharmacokinet. 2008; 47(1(:7-20
- 14. Pranoto, A.X. Better Glucose Profile in Glucose Control of T2DM: the role of basal insulin glargine. *In:* Adi, S., Tjokroprawiro, A., Sutjahjo, A., Nasronudin, Soeroso, J., Pranoto, A., Baskoro, A., Aditiawadana (Eds.). **Pendidikan Kedokteran Berkelanjutan Ilmu Penyakit Dalam XXIV–2009**: 78–104.
- 15. Masharani, U. Diabetes Mellitus and Hypoglycemia. *In:* McPhee, S.J., Papadakis, M.A., **Current Medical Diagnosis and Treatment**, 49th Edition, New York; 2010: The The McGraw–Hill Co., Inc. p. 2782–2859.
- 16. Kroon, L.A., Assemi, M., Carlisle, B.A. Diabetes Mellitus. *In:* Koda-Kimble, M.A., Young, L.Y., Alldredge, B.K., Corelli, R.L., Guglielmo, B.J., Kradjan, W.A., Williams, B.R. (Eds.). **Applied Therapeutics : The Clinical Use of Drugs**, 9th Edition, New York : Lippincott Williams & Wilkins. 2009: 50p2–50p86.
- 17. American Diabetes Association. Standards of Medical Care in Diabetes. **Diab Care** 2010; 2010: 33 (Suppl 1): S11-S61

AUTHORS' CONTRIBUTIONS

Authors contributed equally to all aspects of the study.

PEER REVIEW

Not commissioned; externally peer reviewed.

CONFLICTS OF INTEREST

This research is founded by Grant of Indonesia Managing Higher Education for Relevancy and Eficiency (IMHERE) Project, Directorate of Higher Education, Indonesian Government Click to enable Adobe Flash Player

Click to enable Adobe Flash Player



Editorial Committee

Editor in Chief

Syed Wasif Gillani, Assistant Prof. Dr Azmi Sarriff, Assoc. Prof. Dr

Executive Editor

Syed Azhar Syed Suleiman. (Malaysia) Prof. Dr Mostafa Nejati (Iran) Wafaa Mohamed El-Anor Ahmed Rashed (Egypt), Dr Mark Raymond (USA) Prof. Dr Robert Hougland (USA)

Editorial Team Members

Jasmin Musanovic (Bosnia Harzegovina), Dr. Mensura Kudumovic (Bosnia Harzegovina), Dr. Monica Gaidhane (USA), Dr. Mok T. Chong (USA), Assoc. Prof. Dr. Syed Tajuddin Syed Hassan (Malaysia) Dr. Aleth Therese L. Dacanay (Philippine) Dr. Atif Ameen (Pakistan), Dr. Hadzliana Zainal (Malaysia) Ms. Nur Hafzan Md Hanafiah (Malaysia) Ms. Sabariah Ngor Harun (Malaysja) Ms. Nabiel Khan (Saudi Arabia) Mr. Amin Saburi, (Tehran, Iran) M.D. Suzana Tasic Otasevic. (Siberia) Prof. Dr Roberto Frontini (Germany) Dr. Aida Batista (Portugal) Dr. Tony West (UK) Dr. Francesca Venturini (Italy) Dr. Petr Horák (Czech Republic) Dr. Joan Peppard (Ireland) Dr. Peter Halstead (Australia) Dr. Linda Suveges. (Cannada) Dr Carmen Vezina, (Cannada) Prof, Dr Pierre Moreau, (Cannada) Dr Anita Hardon. (Amsterdam, Holland) Prof. Dr Siti Mahsarah Sheikh Ghadzi (Malaysia) Ms. Fatimatuzzahra Abd Aziz (Majaysia) Ms. Adriana Rolim (Brazil), Dr.

Ajit S. Kulkarni (India), Dr. V. Sivajothi (India), Dr. Gajana S. Sanap (India) Dr.

Mithun Singh Rajput (India) Dr.

Jimmy Jose (Oman), Dr.

Vibhor Kumar Jain (India) Dr.

Jagdale Swati Changdeo (India), Dr.

Kartikeyan, M (India) Ms.

Chakraborthy. G. S (India), Dr.

MD, Faiyazuddin (India) Dr.

Pathirage Kamal Perera (Sri Lanka), Dr.

Vijay Kumar (India) Mr.

Beduin Mahanti (India) Dr.

Dibyajyoti Saha (Bangladesh) Dr.

Ranin Magdi Mohamed Ibrahim Soliman (Egypt) Mr.

Sumeet Dwivedi (India) Assistant Prof. Dr.

Kyi Kyi Tha (Malaysia) Dr.

Diana Laila Rahmatillah (Indonesia) Ms.

Re: question for article corrections

Dari: Pharmacy teaching (ijourptp@gmail.com)

Kepada: budiprapti@yahoo.co.id

Tanggal: Selasa, 8 Januari 2013 10.34 WIB

Dear Author

We would like to inform you that our journal have finally achieve the online submission status.. check upload your manuscripts to the following link within 72 hours to get included in our online December issue.

http://iomcworld.com/journals

Authors are required to register to submit articles and it would help us better for the traceability. Looking forward for the article submission.

Regards Admin IJPTP

On Wed, Nov 7, 2012 at 10:50 AM, Budi Suprapti < budiprapti@yahoo.co.id > wrote:

Dear admin IJPTP,

In responds to your acceptance letter (September 4, 2012) for my article with the title "The Effect of

Regular Human Insulin and Glulisine Insulin on Blood Glucosa Concentration in Diabetic

Nephropathy Patients ith Hyperglycemia", on September 11, 2012 I have sent email and question for

correction but till now I have not get your responds. My questions are:

- (1) for gramatical correction may I get the file of paper that has been reviewed?
- (2) about the copyright form to IJPTP, how to get it? or I make it by my self?

Thanks, I hope I get your answer as soon as possible.

Regards

Dr. Budi Suprapti, Apt., MSi

Clinical Pharmacy Department

Faculty of Pharmacy Airlangga University

Campus B Jl. Darmawangsa Dalam, Surabaya, Indonesia

Office phone: +62-031-5033710 Fax number: +62-031-5020514 Mobile: +62-08155086694

Email: budiprapti@yahoo.co.id

---- Pesan yang Diteruskan -----

Dari: Budi Suprapti < budiprapti@yahoo.co.id >

Kepada: Pharmacy teaching <ijourptp@gmail.com>

Dikirim: Selasa, 11 September 2012 6:18

Judul: Bls: article corrections

Dear admin IJPTP,

Thanks for the acceptance our paper to be published in IJPTP. To make correction, I have questions:

- (1) for gramatical correction may I get the file of paper that has been reviewed?
- (2) about the copyright form to IJPTP, how to get it? or I make it by my self?

Thanks, I am waiting your answer

Regards

Dr. Budi Suprapti, Apt., MSi

Clinical Pharmacy Department

Faculty of Pharmacy Airlangga University

Campus B Jl. Darmawangsa Dalam, Surabaya, Indonesia

Office phone: +62-031-5033710 Fax number: +62-031-5020514 Mobile: +62-08155086694

Email: budiprapti@yahoo.co.id

Dari: Pharmacy teaching <<u>ijourptp@gmail.com</u>> **Kepada:** Budi Suprapti <<u>budiprapti@yahoo.co.id</u>>

Dikirim: Selasa, 4 September 2012 9:25

Judul: article corrections

Dear Author

We are pleased to inform you that your both article has been accepted in IJPTP, Please see the corrections as follow;

Please recheck the following corrections:

- 1. Grammatical errors
- 2. article format must according to the journal style... please follow authors guidelines
- 3. Referencing style: (is has been suggested that author have to cite at least 2 papers from journal previous issues article)
- 4. Abstract should be comprehensive
- 5. Provide detail information about corresponding author
- 6. signed and scan the copyright form to IJPTP.

If you have any queries please don't hesitate to contact us.

Regards

Admin LIPTP

--

DISCLAIMER

This email is confidential and intended only for the use of the individual or entity named above and may contain information that is privileged. If you are not the intended recipient, you are notified that any dissemination, distribution or copying of this email is strictly prohibited. If you have received this email in error, please notify us immediately by return email or telephone and destroy the original message.

Please report abuse/misuse to: <u>ijourptp@gmail.com</u>. Actions can be taken to further improve the service.

On Thu, Jun 28, 2012 at 11:54 PM, Budi Suprapti < budiprapti@yahoo.co.id> wrote:

Dear IJPTP Editor in chief,

I Have attached an article with the title "THE EFFECT OF REGULAR HUMAN INSULIN AND

GLULISINE INSULIN ON BLOOD GLUCOSA CONCENTRATION IN DIABETIC

NEPHROPATHY PATIENTS WITH HYPERGLYCEMIA", hopefully could be considered to be published in IJPTP.

I hope I get a notification if you have receive this email/article.

Regards,

Dr. Budi Suprapti, Apt., MSi

Clinical Pharmacy Department

Faculty of Pharmacy Airlangga University

Campus B Jl. Darmawangsa Dalam, Surabaya, Indonesia

Office phone: +62-031-5033710 Fax number: +62-031-5020514

Mobile: +62-08155086694

Email: <u>budiprapti@yahoo.co.id</u>

DISCLAIMER

This email is confidential and intended only for the use of the individual or entity named above and may contain information that is privileged. If you are not the intended recipient, you are notified that any dissemination, distribution or copying of this email is strictly prohibited. If you have received this email in error, please notify us immediately by return email or telephone and destroy the original message.

Please report abuse/misuse to: <u>ijourptp@gmail.com</u>. Actions can be taken to futher improve the service.

Bls: article corrections

Dari: Budi Suprapti (budiprapti@yahoo.co.id)

Kepada: ijourptp@gmail.com

Tanggal: Selasa, 11 September 2012 06.18 WIB

Dear admin IJPTP,

Thanks for the acceptance our paper to be published in IJPTP. To make correction, I have questions:

- (1) for gramatical correction may I get the file of paper that has been reviewed?
- (2) about the copyright form to IJPTP, how to get it? or I make it by my self?

Thanks, I am waiting your answer

Regards

Dr. Budi Suprapti, Apt., MSi

Clinical Pharmacy Department

Faculty of Pharmacy Airlangga University

Campus B Jl. Darmawangsa Dalam, Surabaya, Indonesia

Office phone: +62-031-5033710 Fax number: +62-031-5020514 Mobile: +62-08155086694

Email: <u>budiprapti@yahoo.co.id</u>

Dari: Pharmacy teaching <ijourptp@gmail.com> **Kepada:** Budi Suprapti <budiprapti@yahoo.co.id>

Dikirim: Selasa, 4 September 2012 9:25

Judul: article corrections

Dear Author

We are pleased to inform you that your both article has been accepted in IJPTP, Please see the corrections as follow;

Please recheck the following corrections:

- 1. Grammatical errors
- 2. article format must according to the journal style... please follow authors guidelines
- 3. Referencing style: (is has been suggested that author have to cite at least 2 papers from journal previous issues article)
- 4. Abstract should be comprehensive
- 5. Provide detail information about corresponding author
- 6. signed and scan the copyright form to IJPTP.

If you have any queries please don't hesitate to contact us.

Regards Admin IJPTP _

DISCLAIMER

This email is confidential and intended only for the use of the individual or entity named above and may contain information that is privileged. If you are not the intended recipient, you are notified that any dissemination, distribution or copying of this email is strictly prohibited. If you have received this email in error, please notify us immediately by return email or telephone and destroy the original message.

Please report abuse/misuse to: <u>ijourptp@gmail.com</u>. Actions can be taken to further improve the service.

On Thu, Jun 28, 2012 at 11:54 PM, Budi Suprapti < budiprapti@yahoo.co.id > wrote:

Dear IJPTP Editor in chief,

I Have attached an article with the title "THE EFFECT OF REGULAR HUMAN INSULIN AND GLULISINE INSULIN ON BLOOD GLUCOSA CONCENTRATION IN DIABETIC NEPHROPATHY PATIENTS WITH HYPERGLYCEMIA", hopefully could be considered to be published in IJPTP.

I hope I get a notification if you have receive this email/article.

Regards,

Dr. Budi Suprapti, Apt., MSi

Clinical Pharmacy Department

Faculty of Pharmacy Airlangga University

Campus B Jl. Darmawangsa Dalam, Surabaya, Indonesia

Office phone: +62-031-5033710 Fax number: +62-031-5020514

Mobile: +62-08155086694

Email: <u>budiprapti@yahoo.co.id</u>

article corrections

Dari: Pharmacy teaching (ijourptp@gmail.com)

Kepada: budiprapti@yahoo.co.id

Tanggal: Selasa, 4 September 2012 09.25 WIB

Dear Author

We are pleased to inform you that your both article has been accepted in IJPTP, Please see the corrections as follow:

Please recheck the following corrections:

- 1. Grammatical errors
- 2. article format must according to the journal style... please follow authors guidelines
- 3. Referencing style: (is has been suggested that author have to cite at least 2 papers from journal previous issues article)
- 4. Abstract should be comprehensive
- 5. Provide detail information about corresponding author
- 6. signed and scan the copyright form to IJPTP.

If you have any queries please don't hesitate to contact us.

Regards Admin IJPTP

DISCLAIMER

This email is confidential and intended only for the use of the individual or entity named above and may contain information that is privileged. If you are not the intended recipient, you are notified that any dissemination, distribution or copying of this email is strictly prohibited. If you have received this email in error, please notify us immediately by return email or telephone and destroy the original message.

Please report abuse/misuse to: ijourptp@gmail.com. Actions can be taken to further improve the service.

On Thu, Jun 28, 2012 at 11:54 PM, Budi Suprapti < budiprapti@yahoo.co.id > wrote:

Dear IJPTP Editor in chief,

I Have attached an article with the title "THE EFFECT OF REGULAR HUMAN INSULIN AND

GLULISINE INSULIN ON BLOOD GLUCOSA CONCENTRATION IN DIABETIC

NEPHROPATHY PATIENTS WITH HYPERGLYCEMIA", hopefully could be considered to be published in IJPTP.

I hope I get a notification if you have receive this email/article.

Regards,

Dr. Budi Suprapti, Apt., MSi

Clinical Pharmacy Department

Faculty of Pharmacy Airlangga University

Campus B Jl. Darmawangsa Dalam, Surabaya, Indonesia

Office phone: +62-031-5033710 Fax number: +62-031-5020514

Mobile: +62-08155086694

Email: <u>budiprapti@yahoo.co.id</u>

acknowledgement

Dari: Pharmacy teaching (ijourptp@gmail.com)

Kepada: budiprapti@yahoo.co.id

Tanggal: Jumat, 29 Juni 2012 07.53 WIB

Dear Author

We hereby acknowledge the receipt of your manuscript. you will hear once again from us once the review process will be done. Meanwhile if you have any questions or queries please don't hesitate to contact us.

Regards Admin IJPTP

--

DISCLAIMER

This email is confidential and intended only for the use of the individual or entity named above and may contain information that is privileged. If you are not the intended recipient, you are notified that any dissemination, distribution or copying of this email is strictly prohibited. If you have received this email in error, please notify us immediately by return email or telephone and destroy the original message.

Please report abuse/misuse to: <u>ijourptp@gmail.com</u>. Actions can be taken to further improve the service.

On Thu, Jun 28, 2012 at 11:54 PM, Budi Suprapti < budiprapti@yahoo.co.id > wrote:

Dear IJPTP Editor in chief,

I Have attached an article with the title "THE EFFECT OF REGULAR HUMAN INSULIN AND GLULISINE INSULIN ON BLOOD GLUCOSA CONCENTRATION IN DIABETIC

NEPHROPATHY PATIENTS WITH HYPERGLYCEMIA", hopefully could be considered to be published in IJPTP.

I hope I get a notification if you have receive this email/article.

Regards,

Dr. Budi Suprapti, Apt., MSi

Clinical Pharmacy Department

Faculty of Pharmacy Airlangga University

Campus B Jl. Darmawangsa Dalam, Surabaya, Indonesia

Office phone: +62-031-5033710 Fax number: +62-031-5020514

Mobile: +62-08155086694

Email: <u>budiprapti@yahoo.co.id</u>

Bls: [IJPTP] Submission Acknowledgement

Dari: Budi Suprapti (budiprapti@yahoo.co.id)

Kepada: ijourptp@gmail.com

Tanggal: Jumat, 26 April 2013 07.39 WIB

Dear Syed Wasif Gillani Editor of IJPTP

I have question about the editorial process of my paper that has been submitted on Januari 10, 2013. From online management system from Januari 23, 2013 till now there is no progression status, it said still in editing process. Are there any information needed for completion? When this paper will be included in publication?

I am looking forward your answer

Regards,
Budi Suprapti
Department of Clinical Pharmacy
Faculty of Pharmacy
Airlangga University
Surabaya, East Java, Indonesia

Dari: Syed Wasif Gillani <ijourptp@gmail.com> **Kepada:** Mrs budi suprapti <budiprapti@yahoo.co.id>

Dikirim: Kamis, 10 Januari 2013 8:17

Judul: [IJPTP] Submission Acknowledgement

Mrs budi suprapti:

Thank you for submitting the manuscript, "THE EFFECT OF REGULAR HUMAN INSULIN AND GLULISINE INSULIN ON BLOOD GLUCOSA CONCENTRATION IN DIABETIC NEPHROPATHY PATIENTS WITH HYPERGLYCEMIA" to International Journal of Pharmacy Teaching and Practices (IJPTP). With the online journal management system that we are using, you will be able to track its progress through the editorial process by logging in to the journal web site:

Manuscript URL:

http://iomcworld.com/journals/index.php/ijptp/author/submission/15

Username: budiprapti

If you have any questions, please contact me. Thank you for considering this journal as a venue for your work.

Syed Wasif Gillani

International Journal of Pharmacy Teaching and Practices (IJPTP)

International Journal of Pharmacy Teaching and Practices (IJPTP) http://ijptp.iomcworld.com/

IJPTP article submission

Dari: Budi Suprapti (budiprapti@yahoo.co.id)

Kepada: ijourptp@gmail.com

Tanggal: Kamis, 28 Juni 2012 22.54 WIB

Dear IJPTP Editor in chief,

I Have attached an article with the title "THE EFFECT OF REGULAR HUMAN INSULIN AND GLULISINE INSULIN ON BLOOD GLUCOSA CONCENTRATION IN DIABETIC NEPHROPATHY PATIENTS WITH HYPERGLYCEMIA", hopefully could be considered to be published in IJPTP.

I hope I get a notification if you have receive this email/article.

Regards,

Dr. Budi Suprapti, Apt., MSi

Clinical Pharmacy Department

Faculty of Pharmacy Airlangga University

Campus B Jl. Darmawangsa Dalam, Surabaya, Indonesia

Office phone: +62-031-5033710

Fax number: +62-031-5020514

Mobile: +62-08155086694

Email: budiprapti@yahoo.co.id



IJPTP insulin Budi Suprapti Indonesia.doc

208.5kB

question for article corrections

Dari: Budi Suprapti (budiprapti@yahoo.co.id)

Kepada: ijourptp@gmail.com

Tanggal: Rabu, 7 November 2012 09.50 WIB

Dear admin IJPTP,

In responds to your acceptance letter (September 4, 2012) for my article with the title "The Effect of

Regular Human Insulin and Glulisine Insulin on Blood Glucosa Concentration in Diabetic Nephropathy

Patients ith Hyperglycemia", on September 11, 2012 I have sent email and question for correction but

till now I have not get your responds. My questions are:

- (1) for gramatical correction may I get the file of paper that has been reviewed?
- (2) about the copyright form to IJPTP, how to get it? or I make it by my self?

Thanks, I hope I get your answer as soon as possible.

Regards

Dr. Budi Suprapti, Apt., MSi

Clinical Pharmacy Department

Faculty of Pharmacy Airlangga University

Campus B Jl. Darmawangsa Dalam, Surabaya, Indonesia

Office phone: +62-031-5033710 Fax number: +62-031-5020514

Mobile: +62-08155086694

Email: <u>budiprapti@yahoo.co.id</u>

---- Pesan yang Diteruskan -----

Dari: Budi Suprapti

Sudiprapti@yahoo.co.id>
 Kepada: Pharmacy teaching <ijourptp@gmail.com>

Dikirim: Selasa, 11 September 2012 6:18

Judul: Bls: article corrections

Dear admin IJPTP,

Thanks for the acceptance our paper to be published in IJPTP. To make correction, I have questions:

- (1) for gramatical correction may I get the file of paper that has been reviewed?
- (2) about the copyright form to IJPTP, how to get it? or I make it by my self?

Thanks, I am waiting your answer

Regards

Dr. Budi Suprapti, Apt., MSi

Clinical Pharmacy Department

Faculty of Pharmacy Airlangga University

Campus B Jl. Darmawangsa Dalam, Surabaya, Indonesia

Office phone: +62-031-5033710

Fax number: +62-031-5020514 Mobile: +62-08155086694 Email: <u>budiprapti@yahoo.co.id</u>

Dari: Pharmacy teaching <ijourptp@gmail.com> **Kepada:** Budi Suprapti <budiprapti@yahoo.co.id>

Dikirim: Selasa, 4 September 2012 9:25

Judul: article corrections

Dear Author

We are pleased to inform you that your both article has been accepted in IJPTP, Please see the corrections as follow;

Please recheck the following corrections:

- 1. Grammatical errors
- 2. article format must according to the journal style... please follow authors guidelines
- 3. Referencing style: (is has been suggested that author have to cite at least 2 papers from journal previous issues article)
- 4. Abstract should be comprehensive
- 5. Provide detail information about corresponding author
- 6. signed and scan the copyright form to IJPTP.

If you have any queries please don't hesitate to contact us.

Regards Admin IJPTP

--

DISCLAIMER

This email is confidential and intended only for the use of the individual or entity named above and may contain information that is privileged. If you are not the intended recipient, you are notified that any dissemination, distribution or copying of this email is strictly prohibited. If you have received this email in error, please notify us immediately by return email or telephone and destroy the original message.

Please report abuse/misuse to: <u>ijourptp@gmail.com</u>. Actions can be taken to further improve the service.

On Thu, Jun 28, 2012 at 11:54 PM, Budi Suprapti < budiprapti@yahoo.co.id> wrote:

Dear IJPTP Editor in chief,

I Have attached an article with the title "THE EFFECT OF REGULAR HUMAN INSULIN AND GLULISINE INSULIN ON BLOOD GLUCOSA CONCENTRATION IN DIABETIC NEPHROPATHY PATIENTS WITH HYPERGLYCEMIA", hopefully could be considered to be published in IJPTP.

I hope I get a notification if you have receive this email/article.

Regards,

Dr. Budi Suprapti, Apt., MSi

Clinical Pharmacy Department

Faculty of Pharmacy Airlangga University

Campus B Jl. Darmawangsa Dalam, Surabaya, Indonesia

Office phone: +62-031-5033710 Fax number: +62-031-5020514

Mobile: +62-08155086694

Email: budiprapti@yahoo.co.id

[IJPTP] Submission Acknowledgement

Dari: Syed Wasif Gillani (ijourptp@gmail.com)

Kepada: budiprapti@yahoo.co.id

Tanggal: Kamis, 10 Januari 2013 08.16 WIB

Mrs budi suprapti:

Thank you for submitting the manuscript, "THE EFFECT OF REGULAR HUMAN INSULIN AND GLULISINE INSULIN ON BLOOD GLUCOSA CONCENTRATION IN DIABETIC NEPHROPATHY PATIENTS WITH HYPERGLYCEMIA" to International Journal of Pharmacy Teaching and Practices (IJPTP). With the online journal management system that we are using, you will be able to track its progress through the editorial process by logging in to the journal web site:

Manuscript URL:

http://iomcworld.com/journals/index.php/ijptp/author/submission/15

Username: budiprapti

If you have any questions, please contact me. Thank you for considering this journal as a venue for your work.

Syed Wasif Gillani

International Journal of Pharmacy Teaching and Practices (IJPTP)

International Journal of Pharmacy Teaching and Practices (IJPTP) http://ijptp.iomcworld.com/